Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mouse myeloma proteins with lambda 2 and lambda 3 light chains.

T Cotner, K Blaser, J Kriedberg

    Journal of Immunology (Baltimore, Md. : 1950)
    |November 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Genes, structures and function of T lymphocyte antigen receptors.

    Immunology today·2014
    Same author

    Global Allergy Forum and Second Davos Declaration 2013 Allergy: Barriers to cure--challenges and actions to be taken.

    Allergy·2014
    Same author

    Davos declaration: allergy as a global problem.

    Allergy·2012
    Same author

    Suppression of circulating antibodies in pyridoxin deficiency.

    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·2010
    Same author

    Primary systemic amyloidosis.

    The American journal of medicine·2010
    Same author

    Diamine oxidase (histaminase) activity of kidney and other organs in the hypersensitive state.

    The American journal of physiology·2010

    Researchers screened mouse myeloma proteins for similarities to L315, identifying four proteins with light chains serologically indistinguishable from lambda 2. Further analysis revealed three of these possess a distinct lambda 3 light chain type.

    Area of Science:

    • Immunology
    • Biochemistry
    • Molecular Biology

    Background:

    • Myeloma proteins, specifically immunoglobulin light chains, are crucial biomarkers in multiple myeloma research.
    • The L315 myeloma protein, characterized by its lambda 2 light chain, serves as a reference standard for comparative studies.
    • Identifying novel myeloma light chain variants can enhance understanding of B-cell malignancies and antibody diversity.

    Purpose of the Study:

    • To serologically screen a large cohort of mouse myeloma tumors for proteins expressing light chains similar to the L315 myeloma protein.
    • To characterize the identified myeloma proteins and their light chains, comparing them to the known lambda 2 and lambda 3 types.
    • To investigate the structural and serological similarities and differences among newly identified myeloma light chains.

    Related Experiment Videos

    Main Methods:

    • Serological screening of serum and ascites fluid from 260 mouse myeloma tumors.
    • Immunological assays to detect myeloma proteins with light chains resembling L315 (lambda 2).
    • Analysis of C-terminal amino acids and tryptic peptides to confirm structural homology.

    Main Results:

    • Four myeloma proteins (from TEPC-952, CBPC-49, ABPC-72, and SAPC-15) were identified with light chains serologically similar to L315.
    • TEPC-952 myeloma protein's light chain was confirmed as lambda 2, consistent with L315.
    • CBPC-49, ABPC-72, and SAPC-15 myeloma proteins were found to possess a distinct light chain type, designated lambda 3, despite serological similarities.

    Conclusions:

    • The study successfully identified novel myeloma proteins in mice exhibiting light chains similar to the L315 lambda 2 protein.
    • Distinction between lambda 2 and lambda 3 light chain types was confirmed through serological and biochemical analyses.
    • These findings contribute to the classification of immunoglobulin light chains and the understanding of myeloma heterogeneity.